A natural language processing system for the efficient updating of highly curated pathophysiology mechanism knowledge graphs von Babaiha, Negin Sadat, Elsayed, Hassan, Zhang, Bide, Kaladharan, Abish, Sethumadhavan, Priya, Schultz, Bruce, Klein, Jürgen, Freudensprung, Bruno, Lage-Rupprecht, Vanessa, Kodamullil, Alpha Tom, Jacobs, Marc, Geissler, Stefan, Madan, Sumit, Hofmann-Apitius, Martin

Volltext

PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis von Bouhnik, Yoram, Fautrel, Bruno, Beaugerie, Laurent, Pelletier, Anne-Laure, Martinez-Vinson, Christine, Freudensprung, Ulrich, Brigui, Amira, Addison, Janet

Volltext

Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study von Fautrel, Bruno, Bouhnik, Yoram, Dieude, Philippe, Richette, Pascal, Dougados, Maxime, Freudensprung, Ulrich, Brigui, Amira, Addison, Janet

Volltext

First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE von Bachelot, Thomas Denis, Ciruelos, Eva, Peretz-Yablonski, Tamar, Puglisi, Fabio, Schneeweiss, Andreas, Campone, Mario, Coudert, Bruno P., Kaufman, Bella, Wardley, Andrew M., Bastiere-Truchot, Lydie, Freudensprung, Ulrich, Restuccia, Eleonora, Miles, David

Volltext